Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
US-2024246901-A1 · Jul 25, 2024 · US
US9505733B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9505733-B2 |
| Application number | US-201514694588-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 23, 2015 |
| Priority date | Nov 18, 2011 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention discloses single step, highly enantioselective catalytic oxidative cyclization process for the synthesis of 3-substituted chiral phthalides. In particular, the invention discloses asymmetric synthesis of chiral phthalides via synergetic nitrile accelerated oxidative cyclization of o-cyano substituted aryl alkenes in high yield and enantiomeric excess (ee) in short reaction time. Also, disclosed herein is “one-pot” asymmetric synthesis of biologically important natural compounds having 3-substituted chiral phthalide structural framework in the molecule.
Opening claim text (preview).
The invention claimed is: 1. A synthesis of compound (3) comprising (a) reacting an o-cyano substituted aryl alkene of Formula I with AD-mix-β in the presence of a solvent at room temperature ranging between 25-35° C. for a period ranging between 3-7 h to form a cyclic amino ether (b) hydrolyzing the cyclic amino ether with water to form the lactone of Formula II; wherein AD-mix-β comprises potassium osmate K 2 OsO 2 (OH) 4 ; potassium ferricyanide K 3 Fe(CN) 6 ; potassium carbonate; and chiral ligand (DHQD) 2 PHAL; and wherein R 1 , R 2 , R 3 and R4 are hydrogen; and R 5 is C 4 H 9 to form compound (21) (c) carrying out Barton-Mccombie deoxygenation of compound (21) with 1,1-thiocarbonyl diimidazole in the presence of dichloromethane as solvent at 25-35° C. for 10-14 h followed by treatment with tributyltinhydride in the presence of catalytic amount of azobisisobutyronitrile for 20-40 min to obtain compound (3). 2. A synthesis of compound (2a) comprising (a) reacting an o-cyano substituted aryl alkene of Formula I with AD-mix-β in the presence of a solvent at room temperature ranging between 25-35° C. for a period ranging between 3-7 h to form a cyclic amino ether (b) hydrolyzing the cyclic amino ether with water to form the lactone of Formula II; wherein AD-mix-β comprises osmate K 2 OsO 2 (OH 4 ); potassium ferricyanide K 3 Fe(CN) 6 ; potassium carbonate; and chiral ligand (DHQD) 2 PHAL; and wherein R 1 and R 3 are hydrogen, R 2 and R 4 are —OMe, and R 5 is unsubstituted phenyl; to form compound (19) (c) adding BBr3 and an organic solvent to compound (19) followed by stirring at 10° C. to 25° C. for 6-8 h to obtain compound (2a). 3. A synthesis of compound (20) comprising (a) reacting an o-cyano substituted aryl alkene of Formula I with AD-mix-β in the presence of a solvent at room temperature ranging between 25-35° C. for a period ranging between 3-7 h to form a cyclic amino ether (b) hydrolyzing the cyclic amino ether with water to form the lactone of Formula II; wherein AD-mix-β comprises potassium osmate K 2 OsO 2 (OH) 4 ; potassium ferricyanide K 3 Fe(CN) 6 ; potassium carbonate; and chiral ligand (DHQD) 2 PHAL; and wherein R 1 and R 3 are hydrogen, R 2 and R4 are —OMe and R 5 is —Me; to form compound (18) (c) adding BBr3 and an organic solvent to compound (18), followed by stirring at 10° C. to 25° C. for 6-8 h to obtain compound (20).
Naphthofurans; Hydrogenated naphthofurans · CPC title
Ortho-condensed systems · CPC title
with one oxygen atom directly attached in position 1 or 3 · CPC title
Asymmetric syntheses · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.